Clinical Trial Update: A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a cryopreserved formulation of OTL-103 for Wiskott-Aldrich Syndrome. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wiskott-aldrich Syndrome

Drugs mentioned

• OTL-103

Snippet

Sponsor: Fondazione Telethon | Conditions: Wiskott-Aldrich Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING